Autopsy report · NCT01627379

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

“Sponsor decision due to recommendation of the IDMC.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years before it stopped.
• 300 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

AIO-Studien-gGmbH

Sponsor type

University, hospital or other

Conditions

Esophageal Squamous Cell Cancer

Interventions

Cisplatin, 5-FU; Panitumumab

Participants

300 (planned, not actual)

Sites

1

Countries

Germany

Trials that died the same way

• A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
  “Sponsor decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.